CSS
MDGL icon

Cubist Systematic Strategies’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cubist Systematic Strategies’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$8.2M Buy
+17,889
New +$6.67M 0.04% 667
2025
Q2 		– Sell
-19,827
Closed -$5.91M – 3315
2025
Q1 		$6.57M Buy
+19,827
New +$6.51M 0.04% 725
2024
Q2 		– Sell
-9,013
Closed -$2.41M – 3605
2024
Q1 		$2.41M Buy
9,013
+7,291
+423% +$1.72M 0.01% 1500
2023
Q4 		$398K Buy
+1,722
New +$301K ﹤0.01% 2645
2023
Q2 		– Sell
-18,609
Closed -$4.51M – 3980
2023
Q1 		$4.51M Buy
18,609
+6,708
+56% +$1.83M 0.03% 1023
2022
Q4 		$3.45M Buy
11,901
+1,238
+12% +$121K 0.02% 1359
2022
Q3 		$693K Buy
10,663
+6,963
+188% +$484K ﹤0.01% 2912
2022
Q2 		$265K Sell
3,700
-2,201
-37% -$162K ﹤0.01% 3523
2022
Q1 		$579K Sell
5,901
-10,943
-65% -$923K ﹤0.01% 2440
2021
Q4 		$1.43M Buy
16,844
+14,824
+734% +$1.22M 0.01% 1642
2021
Q3 		$161K Sell
2,020
-25,644
-93% -$2.22M ﹤0.01% 2641
2021
Q2 		$2.69M Buy
+27,664
New +$3.27M 0.03% 901
2021
Q1 		– Sell
-15,281
Closed -$1.7M – 2918
2020
Q4 		$1.7M Buy
15,281
+8,168
+115% +$998K 0.02% 1054
2020
Q3 		$845K Buy
7,113
+3,963
+126% +$430K 0.01% 1440
2020
Q2 		$357K Buy
3,150
+750
+31% +$73.8K 0.01% 1767
2020
Q1 		$160K Sell
2,400
-11,097
-82% -$925K ﹤0.01% 1800
2019
Q4 		$1.23M Buy
13,497
+6,404
+90% +$621K 0.02% 1032
2019
Q3 		$612K Buy
7,093
+4,377
+161% +$411K 0.01% 1198
2019
Q2 		$285K Buy
2,716
+1,228
+83% +$132K 0.01% 1845
2019
Q1 		$186K Buy
1,488
+255
+21% +$31.7K 0.01% 1823
2018
Q4 		$139K Sell
1,233
-753
-38% -$117K 0.01% 1670
2018
Q3 		$425K Buy
+1,986
New +$498K 0.02% 942
2018
Q1 		– Sell
-1,327
Closed -$122K – 1967
2017
Q4 		$122K Buy
+1,327
New +$75.8K 0.01% 1656
2015
Q1 		– Sell
-1,918
Closed -$178K – 2002
2014
Q4 		$178K Buy
1,918
+1,239
+182% +$128K 0.01% 1556
2014
Q3 		$72K Buy
+679
New +$94.4K ﹤0.01% 1597

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Cubist Systematic Strategies's MDGL Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2025: 17,889 shares worth $8.2M. The stake represents 0.04% of the portfolio and ranks #667 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in MDGL as recently as Q1 2025.

Cubist Systematic Strategies first reported a position in MDGL in Q3 2014 and has held it in 25 quarters since. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

  • Cubist Systematic Strategies held 17,889 shares of Madrigal Pharmaceuticals worth $8.2M as of Q3 2025.
  • Madrigal Pharmaceuticals was a new Cubist Systematic Strategies position in Q3 2025.
  • Madrigal Pharmaceuticals made up 0.04% of Cubist Systematic Strategies's portfolio in Q3 2025, its #667 holding.
  • Cubist Systematic Strategies first reported a position in Madrigal Pharmaceuticals in Q3 2014 and has held it in 25 quarters since.
  • 352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.